AML
MCID: LKM061
MIFTS: 84

Leukemia, Acute Myeloid (AML)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid 56 37
Acute Myeloid Leukemia 12 74 52 58 73 36 29 6 42 15 17
Leukemia, Acute Myelogenous 56 73 13 39
Acute Myelogenous Leukemia 12 74 52 58
Aml 56 58 73 3
Leukemia, Acute Myeloid, Susceptibility to 56 29 6
Acute Undifferentiated Leukemia 58 54 71
Acute Myeloblastic Leukemia 12 74 73
Acute Myeloid Leukemia with Multilineage Dysplasia 58 6
Acute Leukemia of Ambiguous Lineage 58 6
Leukemia, Myelocytic, Acute 12 71
Acute Myelocytic Leukemia 74 73
Leukemia, Myeloid, Acute 43 39
Acute Myeloid Leukaemia 12 15
Secondary Aml 58 54
Therapy Related Acute Myeloid Leukemia and Myelodysplastic Syndrome 58
Acute Myeloid Leukaemia with Myelodysplasia-Related Features 58
Acute Myeloid Leukemia, Minimal Differentiation, Fab M0 58
Leukemia, Acute Myeloid, Reduced Survival in, Somatic 56
Acute Myeloid Leukemia with Recurrent Genetic Anomaly 58
Acute Myeloid Leukemia with Cebpa Somatic Mutations 58
Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic 56
Therapy-Related Aml and Myelodysplastic Syndrome 58
Aml with Myelodysplasia-Related Features 58
Acute Leukemia of Indeterminate Lineage 58
Pure Familial Acute Myeloid Leukemia 58
Unclassified Acute Myeloid Leukemia 58
Aml with Recurrent Genetic Anomaly 58
Leukemia, Acute Myeloid, Somatic 56
Aml with Cebpa Somatic Mutations 58
Inherited Acute Myeloid Leukemia 58
Secondary Acute Myeloid Leukemia 58
Acute Non-Lymphoblastic Leukemia 73
Acute Myeloid Leukemia, Somatic 56
Aml with Multilineage Dysplasia 58
Mixed Phenotype Acute Leukemia 58
Acute Non-Lymphocytic Leukemia 73
Acute Myeloblastic Leukaemia 12
Aml - Acute Myeloid Leukemia 12
Mixed Lineage Acute Leukemia 58
Acute Myelogenous Leukaemia 12
Acute Biphenotypic Leukemia 71
Hybrid Acute Leukemia 58
Pure Familial Aml 58
Unclassified Aml 58
Inherited Aml 58
Familial Aml 58
Mpal 58

Characteristics:

Orphanet epidemiological data:

58
acute myeloid leukemia
Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Denmark),1-9/100000 (United States); Age of onset: All ages; Age of death: any age;
acute leukemia of ambiguous lineage
Age of onset: All ages;

OMIM:

56
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations
many genes with somatic mutation


HPO:

31
leukemia, acute myeloid:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:9119
OMIM 56 601626
KEGG 36 H00003
ICD9CM 34 205.0
MeSH 43 D015470
NCIt 49 C27753
SNOMED-CT 67 17788007
MESH via Orphanet 44 D015456 D015470
ICD10 via Orphanet 33 C92.0 C92.8 C95.0
UMLS via Orphanet 72 C0023464 C0023467 C0280141 more
UMLS 71 C0023464 C0023467 C0280141

Summaries for Leukemia, Acute Myeloid

MedlinePlus : 42 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Bleeding under the skin Weakness or feeling tired Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to leukemia and core binding factor acute myeloid leukemia, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Acute myeloid leukemia and Transcriptional misregulation in cancer. The drugs Dopamine and Micafungin have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are acute myeloid leukemia and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases : 52 Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow . Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue ; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders , inherited syndromes , environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor . Treatment may include a combination of chemotherapy , radiation therapy , bone marrow transplant and/or other drug therapy.

CDC : 3 Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig's disease, is a progressive disease that attacks the nerve cells that control voluntary movement. The National ALS Registry is a congressionally mandated registry for persons in the U.S. with ALS. It is the only population-based registry in the U.S. that collects information to help scientists learn more about who gets ALS and its causes. No one knows for sure what causes ALS and currently there is no cure.

KEGG : 36 Acute myeloid leukemia (AML) is a disease that is characterized by uncontrolled proliferation of clonal neoplastic cells and accumulation in the bone marrow of blasts with an impaired differentiation program. AML accounts for approximately 80% of all adult leukemias and remains the most common cause of leukemia death. Two major types of genetic events have been described that are crucial for leukemic transformation. A proposed necessary first event is disordered cell growth and upregulation of cell survival genes. The most common of these activating events were observed in the RTK Flt3, in N-Ras and K-Ras, in Kit, and sporadically in other RTKs. Alterations in myeloid transcription factors governing hematopoietic differentiation provide second necessary event for leukemogenesis. Transcription factor fusion proteins such as PML-RARalpha (in Acute promyelocytic leukemia, a subtype of AML), AML-ETO or PLZF-RARalpha block myeloid cell differentiation by repressing target genes. In other cases, the transcription factors themselves are mutated.

UniProtKB/Swiss-Prot : 73 Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia : 74 Acute myeloblastic leukemia is a form of myeloid leukemia affecting... more...

More information from OMIM: 601626

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1384)
# Related Disease Score Top Affiliating Genes
1 leukemia 36.3 TP53 TERT RUNX1 PICALM NPM1 KRAS
2 core binding factor acute myeloid leukemia 35.7 RUNX1 KRAS KIT JAK2 HRAS FLT3
3 myeloid leukemia 35.6 TP53 TERT RUNX1 PICALM NUP214 NPM1
4 cytogenetically normal acute myeloid leukemia 35.3 NPM1 IDH2 IDH1 FLT3 CEBPA
5 acute erythroid leukemia 34.9 TP53 PICALM JAK2 GATA2 CEBPA
6 medulloblastoma 34.4 TP53 TERT KIT JAK2 IDH1 HRAS
7 acute myeloid leukemia with t(8;21)(q22;q22) translocation 34.4 RUNX1 KIT FLT3 CEBPA
8 myelodysplastic syndrome 34.3 TP53 TERT RUNX1 NUP214 NPM1 KRAS
9 diamond-blackfan anemia 34.2 TP53 TERT NPM1 JAK2 GATA2
10 cebpa-associated familial acute myeloid leukemia 34.1 TERT RUNX1 PICALM NUP214 NPM1 MLLT10
11 childhood leukemia 33.8 TP53 RUNX1 ETV6
12 acute leukemia 33.6 RUNX1 NPM1 MLLT10 KRAS KIT JAK2
13 myelofibrosis 33.6 TP53 RUNX1 NPM1 KIT JAK2 IDH2
14 leukemia, acute lymphoblastic 33.4 TP53 RUNX1 PICALM MLLT10 KRAS KIT
15 acute promyelocytic leukemia 33.4 TP53 TERT RUNX1 NPM1 KRAS HRAS
16 wilms tumor 1 33.0 TP53 TERT NPM1 KRAS KIT HRAS
17 myeloma, multiple 32.9 TP53 KRAS KIT JAK2 IDH2 IDH1
18 leukemia, chronic lymphocytic 32.8 TP53 NPM1 KRAS KIT JAK2 HRAS
19 myeloproliferative neoplasm 32.7 RUNX1 KIT JAK2 IDH1 HRAS FLT3
20 hematologic cancer 32.7 TP53 RUNX1 PICALM NPM1 MLLT10 KIT
21 sarcoma 32.6 TP53 NPM1 KRAS KIT JAK2 HRAS
22 childhood acute myeloid leukemia 32.6 NPM1 KIT IDH2 IDH1 HRAS FLT3
23 essential thrombocythemia 32.6 TP53 TERT KRAS KIT JAK2 IDH2
24 chronic myelomonocytic leukemia 32.6 TP53 RUNX1 NPM1 KRAS KIT JAK2
25 leukemia, chronic myeloid 32.5 TP53 RUNX1 NPM1 KRAS KIT JAK2
26 juvenile myelomonocytic leukemia 32.5 TP53 RUNX1 KRAS JAK2 HRAS FLT3
27 blood platelet disease 32.4 RUNX1 KIT JAK2 FLT3
28 polycythemia vera 32.3 KIT JAK2 IDH2 IDH1 FLT3 ETV6
29 bone marrow cancer 32.3 TP53 NPM1 KIT JAK2 HRAS FLT3
30 pancytopenia 32.3 TP53 TERT RUNX1 KIT FLT3
31 myeloid sarcoma 32.2 NPM1 KIT FLT3
32 atypical chronic myeloid leukemia 32.2 RUNX1 JAK2 FLT3 ETV6
33 li-fraumeni syndrome 32.2 TP53 TERT KRAS IDH1 HRAS
34 precursor t-cell acute lymphoblastic leukemia 32.2 PICALM NUP214 MLLT10 FLT3 ETV6
35 bladder urothelial carcinoma 32.1 TP53 TERT KRAS KIT IDH1 HRAS
36 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 32.1 RUNX1 KIT FLT3 ETV6
37 lymphoma, non-hodgkin, familial 32.1 TP53 NPM1 JAK2 FLT3 ETV6
38 leukemia, acute lymphoblastic 3 32.1 TP53 RUNX1 FLT3 ETV6
39 dyskeratosis congenita 32.0 TP53 TERT NPM1 GATA2
40 pancreatic adenocarcinoma 32.0 TP53 TERT KRAS KIT JAK2 HRAS
41 sm-ahnmd 32.0 KIT JAK2 CHIC2
42 systemic mastocytosis 32.0 KIT JAK2 IDH2 IDH1 DNMT3A CHIC2
43 glioblastoma multiforme 32.0 TP53 TERT KRAS KIT IDH2 IDH1
44 lung cancer susceptibility 3 31.9 TP53 TERT KRAS KIT IDH1 HRAS
45 gastric adenocarcinoma 31.9 TP53 TERT KRAS KIT IDH1 HRAS
46 hemangioma 31.9 TP53 KRAS KIT IDH1
47 acute myeloblastic leukemia with maturation 31.9 NPM1 KIT FLT3
48 myelodysplastic/myeloproliferative neoplasm 31.9 KIT JAK2 HRAS FLT3 ETV6 DNMT3A
49 t-cell acute lymphoblastic leukemia 31.8 TP53 RUNX1 NUP214 FLT3 ETV6 DNMT3A
50 suppression of tumorigenicity 12 31.8 TP53 TERT KRAS KIT IDH1 HRAS

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:



Diseases related to Leukemia, Acute Myeloid

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Human phenotypes related to Leukemia, Acute Myeloid:

31
# Description HPO Frequency HPO Source Accession
1 acute myeloid leukemia 31 HP:0004808

Symptoms via clinical synopsis from OMIM:

56
Hematology:
acute myelogenous leukemia (aml)

Clinical features from OMIM:

601626

UMLS symptoms related to Leukemia, Acute Myeloid:


edema, chest pain, angina pectoris

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

26 (show all 28)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.13 LPP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.13 KRAS LPP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.13 KRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 10.13 LPP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-135 10.13 NUP214
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.13 KRAS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-146 10.13 NUP214
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.13 KRAS
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.13 KRAS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.13 KRAS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-183 10.13 HRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.13 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-196 10.13 KRAS LPP
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.13 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 10.13 KRAS
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.13 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.13 KRAS
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.13 HRAS NUP214
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.13 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.13 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.13 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.13 KRAS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.13 HRAS
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-88 10.13 LPP
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-90 10.13 NUP214
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 10.13 KRAS
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.13 HRAS
28 Reduced mammosphere formation GR00396-S 9.23 CEBPA DNMT3A ETV6 HRAS IDH2 KRAS

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
2 growth/size/body region MP:0005378 10.41 CEBPA DNMT3A ETV6 FLT3 GATA2 HRAS
3 hematopoietic system MP:0005397 10.4 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
4 cardiovascular system MP:0005385 10.39 CEBPA CHIC2 DNMT3A ETV6 GATA2 HRAS
5 homeostasis/metabolism MP:0005376 10.39 CEBPA DNMT3A ETV6 FLT3 GATA2 HRAS
6 mortality/aging MP:0010768 10.39 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
7 endocrine/exocrine gland MP:0005379 10.36 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
8 immune system MP:0005387 10.34 CEBPA CHIC2 DNMT3A ETV6 FLT3 IDH1
9 embryo MP:0005380 10.3 DNMT3A ETV6 GATA2 JAK2 KIT KRAS
10 integument MP:0010771 10.22 CEBPA CHIC2 ETV6 HRAS JAK2 KIT
11 neoplasm MP:0002006 10.18 CEBPA ETV6 FLT3 HRAS IDH2 JAK2
12 liver/biliary system MP:0005370 10.16 CEBPA GATA2 JAK2 KIT KRAS NPM1
13 normal MP:0002873 10.02 CEBPA ETV6 GATA2 HRAS JAK2 KIT
14 no phenotypic analysis MP:0003012 9.97 CEBPA ETV6 FLT3 HRAS KIT KRAS
15 reproductive system MP:0005389 9.85 CEBPA CHIC2 DNMT3A GATA2 JAK2 KIT
16 pigmentation MP:0001186 9.65 CHIC2 KIT KRAS PICALM TP53
17 respiratory system MP:0005388 9.61 CEBPA HRAS IDH1 JAK2 KIT KRAS
18 skeleton MP:0005390 9.36 DNMT3A FLT3 HRAS IDH1 IDH2 JAK2

Drugs & Therapeutics for Leukemia, Acute Myeloid

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 610)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4
Nicotine Approved Phase 4 54-11-5 942 89594
5
Lenalidomide Approved Phase 4 191732-72-6 216326
6 Neurotransmitter Agents Phase 4
7 Psychotropic Drugs Phase 4
8 Dopamine Agents Phase 4
9 Antidepressive Agents Phase 4
10 Central Nervous System Stimulants Phase 4
11 Cholinergic Agents Phase 4
12 Nicotinic Agonists Phase 4
13 Angiogenesis Inhibitors Phase 4
14 Imatinib Mesylate Phase 4 220127-57-1 123596
15
Thioguanine Approved Phase 3 154-42-7 2723601
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
18
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
19
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
20
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
21
Lorazepam Approved Phase 3 846-49-1 3958
22
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
23
Iodine Approved, Investigational Phase 3 7553-56-2 807
24
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Dalteparin Approved Phase 3 9005-49-6
27
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
28
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591
29
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
30
Acyclovir Approved Phase 3 59277-89-3 2022
31
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
32
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5362032
33
Enalaprilat Approved Phase 3 76420-72-9 6917719
34
Palivizumab Approved, Investigational Phase 3 188039-54-5
35
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
36
Clove Approved Phase 2, Phase 3 84961-50-2
37
Tazobactam Approved Phase 3 89786-04-9 123630
38
Vancomycin Approved Phase 3 1404-90-6 14969 441141
39
Piperacillin Approved Phase 3 66258-76-2 43672
40
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
41
Morphine Approved, Investigational Phase 3 57-27-2 5288826
42
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
43
Ofloxacin Approved Phase 3 82419-36-1 4583
44
Atorvastatin Approved Phase 3 134523-00-5 60823
45
Captopril Approved Phase 3 62571-86-2 44093
46
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
47
Nalbuphine Approved Phase 3 20594-83-6 5311304 5360630
48
Mycophenolic acid Approved Phase 3 24280-93-1 446541
49
Idarubicin Approved Phase 3 58957-92-9 42890
50
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866

Interventional clinical trials:

(show top 50) (show all 2926)
# Name Status NCT ID Phase Drugs
1 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
2 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
3 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
4 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
6 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
7 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
8 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
9 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
10 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
11 Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis Completed NCT02875743 Phase 4 Posaconazole
12 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
13 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
14 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
15 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
16 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
17 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
18 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
19 Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
20 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
21 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
22 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
23 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
24 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
25 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
26 The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment Recruiting NCT03988205 Phase 4 CPX-351
27 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
28 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
29 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4
30 A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG (TRADEMARKER)) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA Recruiting NCT03727750 Phase 4 Gemtuzumab Ozogamicin
31 A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
32 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
33 PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5 Terminated NCT01198054 Phase 4 Lenalidomide
34 Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib. Terminated NCT00461929 Phase 4
35 Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML Unknown status NCT01696084 Phase 3 CPX-351;7+3 (cytarabine and daunorubicin)
36 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
37 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
38 Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study Unknown status NCT00715637 Phase 3 Daunorubicin and Cytarabine;Amonafide and Cytarabine
39 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
40 A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
41 Protocol for the Treatment of Adults Aged </= 60 Years With De Novo Acute Myeloblastic Leukaemia or Secondary AML or RAEB-T (AML 01/99 Trial) Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
42 Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
43 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
44 Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1) Unknown status NCT01246752 Phase 3 Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
45 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
46 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
47 Randomised Prospective Comparison of the nonmyélo-Ablative Allograft and the Traditional Allograft in Acute Myeloid Leukaemia in Complete Remission of the Adult Unknown status NCT00224614 Phase 3
48 Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
49 Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia ≤65 Years Unknown status NCT02140242 Phase 3 study part 1 - dose daunorubicin
50 HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia Unknown status NCT01484171 Phase 3 idarubicin

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyclophosphamide
Etoposide
etoposide phosphate
Idarubicin
Idarubicin Hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia 29 CBFB CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2 JAK2 KIT KRAS LPP MLLT10 NPM1 NUP214 PICALM RUNX1 SH3GL1 TERT
2 Leukemia, Acute Myeloid, Susceptibility to 29

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

40
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Monocytes, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells Affected by disease
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 29051)
# Title Authors PMID Year
1
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. 61 56 6
21892162 2011
2
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. 61 6 56
19147845 2009
3
Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. 6 61 56
15806161 2005
4
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. 6 56 54
15659725 2005
5
Mutation of CEBPA in familial acute myeloid leukemia. 6 56 61
15575056 2004
6
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. 56 46 61
18308931 2008
7
The JAK2 V617F mutation in de novo acute myelogenous leukemias. 6 56
16247455 2006
8
Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. 56 6
8955068 1996
9
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. 61 56
31665578 2019
10
The spectrum of DNMT3A variants in Tatton-Brown-Rahman syndrome overlaps with that in hematologic malignancies. 61 6
28941052 2017
11
Acute myeloid leukemia-associated DNMT3A p.Arg882His mutation in a patient with Tatton-Brown-Rahman overgrowth syndrome as a constitutional mutation. 61 6
27991732 2017
12
Assessment of Minimal Residual Disease in Standard-Risk AML. 56 61
26789727 2016
13
Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. 56 61
25678665 2015
14
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. 56 61
23634996 2013
15
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. 61 56
22931314 2012
16
Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. 61 56
21454467 2011
17
DNMT3A mutations in acute myeloid leukemia. 61 6
21067377 2010
18
CEBPA-Associated Familial Acute Myeloid Leukemia (AML) 6 61
20963938 2010
19
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 56 61
20368543 2010
20
MicroRNA 29b functions in acute myeloid leukemia. 56 61
19850741 2009
21
Recurring mutations found by sequencing an acute myeloid leukemia genome. 56 61
19657110 2009
22
Mutation in TET2 in myeloid cancers. 56 61
19474426 2009
23
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. 56 61
18450602 2008
24
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. 61 56
17957027 2008
25
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. 61 56
17515897 2007
26
Targeting of CD44 eradicates human acute myeloid leukemic stem cells. 61 56
16998484 2006
27
Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. 61 6
12661007 2003
28
Bilateral orbital myeloid sarcoma as initial sign of acute myeloid leukemia: case report and review of the literature. 61 56
12523908 2003
29
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. 61 6
12384447 2002
30
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. 61 6
11290608 2001
31
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. 61 6
11242107 2001
32
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. 56 61
8516290 1993
33
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. 61 42
32363416 2020
34
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. 56
31578525 2019
35
Prediction of acute myeloid leukaemia risk in healthy individuals. 56
29988082 2018
36
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. 56
29144447 2017
37
BET inhibitor resistance emerges from leukaemia stem cells. 56
26367796 2015
38
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. 56
26367798 2015
39
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. 56
25487151 2015
40
Effect of mutation order on myeloproliferative neoplasms. 6
25671252 2015
41
DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. 56
25079327 2014
42
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. 6
25043017 2014
43
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. 56
24429522 2014
44
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. 56
24522528 2014
45
Genomic landscapes and clonality of de novo AML. 56
24106950 2013
46
Genomic landscapes and clonality of de novo AML. 56
24106951 2013
47
Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 6
23970018 2013
48
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. 56
22504184 2012
49
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. 56
22237025 2012
50
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. 6
22138009 2011

Variations for Leukemia, Acute Myeloid

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

6 (show top 50) (show all 541) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CEBPA NM_001285829.1(CEBPA):c.-26_-19deldeletion Pathogenic 434688 rs1555742213 19:33792982-33792989 19:33302076-33302083
2 CEBPA NM_004364.4(CEBPA):c.119dup (p.Gln41fs)duplication Pathogenic 434686 rs1555742295 19:33793201-33793202 19:33302295-33302296
3 RTEL1 NM_032957.4(RTEL1):c.1207+1G>ASNV Pathogenic 436599 rs1555903332 20:62311300-62311300 20:63679947-63679947
4 CEBPA NM_004364.4(CEBPA):c.195_198delinsACG (p.Ser65fs)indel Pathogenic 644813 19:33793123-33793126 19:33302217-33302220
5 NPM1 NM_199185.3(NPM1):c.782_788delinsCCCTGGCTAGG (p.Trp261fs)indel Pathogenic 632551 rs1561878500 5:170837553-170837559 5:171410549-171410555
6 NPM1 NM_002520.6(NPM1):c.864_873delinsTTTAAGGATTCGTC (p.Trp288fs)indel Pathogenic 810668 5:170837548-170837557 5:171410544-171410553
7 NSD1 NM_022455.4(NSD1):c.1854del (p.Lys618_Val619insTer)deletion Pathogenic 620071 rs1562206791 5:176637251-176637251 5:177210250-177210250
8 DNAJC21 NM_001012339.3(DNAJC21):c.544C>T (p.Arg182Ter)SNV Pathogenic 598950 rs771063992 5:34937536-34937536 5:34937431-34937431
9 CEBPA NM_004364.5(CEBPA):c.168C>A (p.Cys56Ter)SNV Pathogenic 850564 19:33793153-33793153 19:33302247-33302247
10 ETV6 NM_001987.4(ETV6):c.226G>T (p.Glu76Ter)SNV Pathogenic 8984 rs121434637 12:11992136-11992136 12:11839202-11839202
11 ETV6 NM_001987.4(ETV6):c.1307_1308insGGG (p.His436delinsGlnGly)insertion Pathogenic 8985 rs587776710 12:12043928-12043929 12:11890994-11890995
12 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
13 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
14 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
15 KRAS NM_033360.4(KRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 12580 rs112445441 12:25398281-25398281 12:25245347-25245347
16 KRAS NM_033360.4(KRAS):c.35G>A (p.Gly12Asp)SNV Pathogenic 12582 rs121913529 12:25398284-25398284 12:25245350-25245350
17 KRAS NM_033360.4(KRAS):c.35G>T (p.Gly12Val)SNV Pathogenic 12583 rs121913529 12:25398284-25398284 12:25245350-25245350
18 KRAS NM_033360.4(KRAS):c.27_29dup (p.Gly10dup)duplication Pathogenic 12585 rs606231202 12:25398289-25398290 12:25245355-25245356
19 KRAS NM_033360.4(KRAS):c.*12A>TSNV Pathogenic 12587 rs104894360 12:25362838-25362838 12:25209904-25209904
20 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
21 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
22 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
23 TERT NM_198253.3(TERT):c.1891C>T (p.Arg631Trp)SNV Pathogenic 916675 5:1280332-1280332 5:1280217-1280217
24 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
25 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
26 NRAS NM_002524.5(NRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 13901 rs121434596 1:115258744-115258744 1:114716123-114716123
27 NPM1 NM_002520.6(NPM1):c.860_863dupTCTGduplication Pathogenic 13998 rs587776806 5:170837543-170837544 5:171410539-171410540
28 NPM1 NM_002520.6(NPM1):c.863_864insCATG (p.Trp288fs)insertion Pathogenic 13999 rs1554138188 5:170837545-170837546 5:171410541-171410542
29 NPM1 NM_002520.6(NPM1):c.863_864insCGTG (p.Trp288fs)insertion Pathogenic 14000 rs1554138188 5:170837545-170837546 5:171410541-171410542
30 NPM1 NM_002520.6(NPM1):c.863_864insCCTG (p.Trp288fs)insertion Pathogenic 14001 rs1554138189 5:170837544-170837545 5:171410540-171410541
31 JAK2 NM_004972.3(JAK2):c.1849G>T (p.Val617Phe)SNV Pathogenic 14662 rs77375493 9:5073770-5073770 9:5073770-5073770
32 JAK2 NM_004972.3(JAK2):c.1821G>C (p.Lys607Asn)SNV Pathogenic 14663 rs121912472 9:5073742-5073742 9:5073742-5073742
33 CEBPA NM_001285829.1(CEBPA):c.-243_-237deldeletion Pathogenic 17566 rs587776848 19:33793200-33793206 19:33302294-33302300
34 CEBPA NM_001285829.1(CEBPA):c.-210G>TSNV Pathogenic 17567 rs121912791 19:33793173-33793173 19:33302267-33302267
35 CEBPA NM_001285829.1(CEBPA):c.-107A>TSNV Pathogenic 17568 rs28931590 19:33793070-33793070 19:33302164-33302164
36 CEBPA NM_004364.4(CEBPA):c.935_991dup (p.Gln312_Gln330dup)duplication Pathogenic 17569 rs1555741948 19:33792329-33792330 19:33301423-33301424
37 CEBPA NM_004364.4(CEBPA):c.925_951dup (p.Glu309_Leu317dup)duplication Pathogenic 17570 rs1555741967 19:33792369-33792370 19:33301463-33301464
38 CEBPA NM_001285829.1(CEBPA):c.-147_-144dupduplication Pathogenic 17571 rs587776849 19:33793106-33793107 19:33302200-33302201
39 CEBPA NM_001285829.1(CEBPA):c.-290deldeletion Pathogenic 17572 rs137852728 19:33793253-33793253 19:33302347-33302347
40 CEBPA NM_001285829.1(CEBPA):c.-217deldeletion Pathogenic 21396 rs137852730 19:33793180-33793180 19:33302274-33302274
41 CEBPA NM_004364.4(CEBPA):c.198_201dupCTAC (p.Ile68Leufs*41)duplication Pathogenic 21397 rs137852731 19:33793119-33793120 19:33302213-33302214
42 CEBPA NM_004364.4(CEBPA):c.217_218insC (p.Phe73fs)insertion Pathogenic 21398 rs137852733 19:33793103-33793104 19:33302197-33302198
43 CEBPA NM_004364.4(CEBPA):c.318_319dupTG (p.Asp107Valfs*54)duplication Pathogenic 21399 rs137852732 19:33793001-33793002 19:33302095-33302096
44 CEBPA NM_004364.4(CEBPA):c.68dupC (p.His24Alafs)duplication Pathogenic 21401 rs137852728 19:33793252-33793253 19:33302346-33302347
45 FLT3 NM_004119.3(FLT3):c.2520_2521insGGATCC (p.Asn841_Tyr842insGlySer)insertion Pathogenic 16271 rs398122514 13:28592624-28592625 13:28018487-28018488
46 FLT3 NM_004119.3(FLT3):c.2504A>T (p.Asp835Val)SNV Pathogenic 16272 rs121909646 13:28592641-28592641 13:28018504-28018504
47 FLT3 NM_004119.3(FLT3):c.2503G>C (p.Asp835His)SNV Pathogenic 16273 rs121913488 13:28592642-28592642 13:28018505-28018505
48 FLT3 NM_004119.3(FLT3):c.2503G>A (p.Asp835Asn)SNV Pathogenic 16274 rs121913488 13:28592642-28592642 13:28018505-28018505
49 FLT3 NM_004119.3(FLT3):c.2503G>T (p.Asp835Tyr)SNV Pathogenic 16276 rs121913488 13:28592642-28592642 13:28018505-28018505
50 GATA2 NM_001145661.2(GATA2):c.1192C>T (p.Arg398Trp)SNV Pathogenic 29709 rs387906629 3:128200113-128200113 3:128481270-128481270

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

73
# Symbol AA change Variation ID SNP ID
1 CEBPA p.His84Leu VAR_072677 rs28931590
2 DNMT3A p.Arg882Cys VAR_067236 rs377577594
3 DNMT3A p.Arg882His VAR_067237 rs147001633
4 JAK2 p.Lys607Asn VAR_032696 rs121912472
5 JAK2 p.Val617Phe VAR_032697 rs77375493
6 SETBP1 p.Gly870Ser VAR_063809 rs267607040
7 SETBP1 p.Ser854Ala VAR_069848
8 SETBP1 p.Gly870Arg VAR_069854
9 SETBP1 p.Ile871Ser VAR_069856

Copy number variations for Leukemia, Acute Myeloid from CNVD:

7 (show top 50) (show all 491)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13336 1 1 124300000 Insertion Acute myeloid leukemia
2 13759 1 1 28000000 Deletion Acute myeloid leukemia
3 14790 1 110122000 110569000 Gain or loss Acute myeloid leukemia
4 17466 1 142902432 245422360 Duplication Acute myeloid leukemia
5 18096 1 143961000 247125000 Gain or loss Acute myeloid leukemia
6 20826 1 154656757 154656845 Amplification Acute myeloid leukemia
7 24589 1 182359000 182787000 Loss Acute myeloid leukemia
8 26098 1 197094625 197094734 Amplification Acute myeloid leukemia
9 26100 1 197094796 197094905 Amplification Acute myeloid leukemia
10 27148 1 204981000 205049000 Gain or loss Acute myeloid leukemia
11 27263 1 206041820 206041907 Amplification Acute myeloid leukemia
12 27859 1 214500000 224100000 Deletion Acute myeloid leukemia
13 28491 1 222606000 222909000 Gain or loss Acute myeloid leukemia
14 29341 1 230606000 230646000 Gain or loss Acute myeloid leukemia
15 32943 1 40683565 40683656 Amplification Acute myeloid leukemia
16 32944 1 40686494 40686582 Amplification Acute myeloid leukemia
17 33084 1 42072000 42456000 Gain or loss Acute myeloid leukemia
18 35033 1 5913000 7696000 Gain or loss Acute myeloid leukemia
19 35608 1 65296705 65296779 Amplification Acute myeloid leukemia
20 35769 1 67074000 69951000 Gain or loss Acute myeloid leukemia
21 36085 1 71305902 71305987 Amplification miR-186 Acute myeloid leukemia
22 38187 10 1 6700000 Insertion IL15RA Acute myeloid leukemia
23 38188 10 1 6700000 Insertion PRKCQ Acute myeloid leukemia
24 38677 10 104186259 104186331 Deletion Acute myeloid leukemia
25 38804 10 105144000 105144148 Deletion Acute myeloid leukemia
26 39144 10 110889374 110889450 Deletion Acute myeloid leukemia
27 39902 10 122017230 122017301 Deletion let-7a-2 Acute myeloid leukemia
28 41668 10 21893278 22027081 Loss MLLT10 Acute myeloid leukemia
29 41990 10 27075530 27189965 Translate SSH3BP1 Acute myeloid leukemia
30 43278 10 46100000 49900000 Copy number GDF10 Acute myeloid leukemia
31 44445 10 57165247 57165335 Deletion Acute myeloid leukemia
32 44874 11 64658609 64658718 Deletion miR-192 Acute myeloid leukemia
33 45369 10 70521000 135283000 Gain Acute myeloid leukemia
34 47681 10 96486000 100815000 Loss Acute myeloid leukemia
35 49592 11 108316750 133951370 Triplication Acute myeloid leukemia
36 50142 11 114500000 121200000 Copy number MLL Acute myeloid leukemia
37 50190 11 115400000 120700000 Insertion DDX6 Acute myeloid leukemia
38 50191 11 115400000 120700000 Insertion ETS1 Acute myeloid leukemia
39 50192 11 115400000 120700000 Insertion FLI1 Acute myeloid leukemia
40 50193 11 115400000 120700000 Insertion MLL Acute myeloid leukemia
41 50261 11 116297361 116448564 Loss Acute myeloid leukemia
42 50346 11 117203762 118563610 Amplification Acute myeloid leukemia
43 50385 11 117603158 117860329 Duplication Acute myeloid leukemia
44 50437 11 117820656 117856311 Gain MLL Acute myeloid leukemia
45 50640 11 118585028 127052111 Deletion Acute myeloid leukemia
46 51468 11 126537000 130235000 Gain Acute myeloid leukemia
47 51512 11 127394408 133951311 Amplification Acute myeloid leukemia
48 52810 11 2016406 2019065 Methylation H19 Acute myeloid leukemia
49 53744 11 32409321 32457081 Mutation WT1 Acute myeloid leukemia
50 54217 11 39671000 39746000 Loss Acute myeloid leukemia

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

36
# Name Kegg Source Accession
1 Acute myeloid leukemia hsa05221
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.33 TP53 KRAS KIT JAK2 HRAS FLT3
2
Show member pathways
13.27 TP53 NUP214 KRAS KIT JAK2 HRAS
3
Show member pathways
12.7 TP53 TERT KRAS KIT JAK2 HRAS
4 12.66 TP53 KRAS KIT HRAS FLT3
5
Show member pathways
12.65 TP53 TERT KRAS KIT HRAS
6
Show member pathways
12.45 TP53 RUNX1 KRAS KIT HRAS FLT3
7 12.37 RUNX1 KIT JAK2 GATA2 CEBPA
8 12.33 TP53 TERT RUNX1 KRAS KIT JAK2
9
Show member pathways
12.3 TP53 JAK2 HRAS CEBPA
10 12.22 TP53 TERT KRAS HRAS
11
Show member pathways
12.2 KRAS JAK2 HRAS FLT3
12
Show member pathways
12.13 TP53 KRAS JAK2 HRAS
13
Show member pathways
12 KRAS JAK2 HRAS
14 11.95 NPM1 KIT JAK2 FLT3
15 11.94 TP53 RUNX1 FLT3 ETV6 CEBPA
16
Show member pathways
11.91 TP53 KRAS JAK2 HRAS
17 11.71 TP53 TERT NPM1
18 11.64 TP53 KRAS HRAS
19
Show member pathways
11.59 KRAS KIT HRAS FLT3
20 11.57 TP53 KRAS HRAS
21 11.54 TP53 HRAS CEBPA
22
Show member pathways
11.53 KRAS JAK2 HRAS
23 11.51 TERT NPM1 GATA2
24 11.19 NPM1 KRAS HRAS
25 11.01 TP53 KRAS KIT IDH2 IDH1 HRAS
26 10.92 FLT3 ETV6 DNMT3A
27 10.75 KRAS HRAS
28
Show member pathways
10.74 IDH2 IDH1

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 TP53 TERT RUNX1 NUP214 NPM1 MLLT10
2 nucleus GO:0005634 9.83 TP53 TERT RUNX1 PICALM NUP214 NPM1
3 cytosol GO:0005829 9.47 TP53 TERT PICALM NUP214 NPM1 MLLT10

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.1 TP53 RUNX1 NPM1 KIT ETV6 CEBPA
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.09 TP53 RUNX1 GATA2 ETV6 DNMT3A CEBPA
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 TP53 RUNX1 NPM1 MLLT10 HRAS GATA2
4 negative regulation of cell proliferation GO:0008285 9.97 TP53 NPM1 JAK2 HRAS CEBPA
5 positive regulation of cell proliferation GO:0008284 9.95 NPM1 KRAS KIT JAK2 HRAS FLT3
6 MAPK cascade GO:0000165 9.85 KRAS KIT JAK2 HRAS FLT3
7 positive regulation of gene expression GO:0010628 9.85 TP53 KRAS KIT HRAS GATA2 CEBPA
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.81 KIT JAK2 FLT3
9 negative regulation of neuron apoptotic process GO:0043524 9.81 TERT KRAS JAK2 HRAS
10 liver development GO:0001889 9.8 KRAS HRAS CEBPA
11 hematopoietic progenitor cell differentiation GO:0002244 9.78 TP53 KIT FLT3
12 Ras protein signal transduction GO:0007265 9.77 TP53 KRAS HRAS
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 KIT JAK2 FLT3
14 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.67 TP53 TERT GATA2
15 replicative senescence GO:0090399 9.64 TP53 TERT
16 positive regulation of phospholipase C activity GO:0010863 9.64 KIT HRAS
17 negative regulation of gene expression GO:0010629 9.63 TP53 TERT RUNX1 PICALM HRAS GATA2
18 negative regulation of glial cell proliferation GO:0060253 9.62 TERT IDH2
19 cell aging GO:0007569 9.61 TP53 NPM1 HRAS
20 NADP metabolic process GO:0006739 9.58 IDH2 IDH1
21 ribosomal large subunit export from nucleus GO:0000055 9.58 NUP214 NPM1
22 ribosomal small subunit export from nucleus GO:0000056 9.56 NUP214 NPM1
23 positive regulation of MAP kinase activity GO:0043406 9.56 KRAS KIT HRAS FLT3
24 response to isolation stress GO:0035900 9.55 KRAS HRAS
25 isocitrate metabolic process GO:0006102 9.54 IDH2 IDH1
26 myeloid progenitor cell differentiation GO:0002318 9.52 KIT FLT3
27 cytokine-mediated signaling pathway GO:0019221 9.43 TP53 KRAS KIT JAK2 FLT3 CEBPA
28 glyoxylate cycle GO:0006097 9.32 IDH2 IDH1
29 hemopoiesis GO:0030097 9.02 RUNX1 PICALM KIT GATA2 FLT3

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TP53 TERT RUNX1 PICALM NUP214 NPM1
2 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.8 TP53 RUNX1 GATA2 ETV6 CEBPA
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.73 TP53 RUNX1 GATA2 ETV6 DNMT3A CEBPA
4 transcription factor binding GO:0008134 9.72 TP53 NPM1 GATA2 DNMT3A CEBPA
5 chromatin binding GO:0003682 9.63 TP53 NPM1 MLLT10 GATA2 DNMT3A CEBPA
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
7 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Leukemia, Acute Myeloid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek